P18.02 Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer

Abstract

Introduction: Previous study demonstrated that the baseline lung immune prognostic index (LIPI) was a potential biomarker which can identify advanced non-small cell lung cancer (NSCLC) patients who will benefit from treatment with immune checkpoint inhibitor (ICI). However, a recent study found that the LIPI might be an important prognostic biomarker irrespective of treatment modality for patients with metastatic NSCLC. It remains unclear whether LIPI is associated with long-term outcomes in unresected stage III NSCLC. Methods: Patients with LA-NSCLC treated with definitive radiotherapy (RT) between 2000 to 2017 were retrospectively reviewed. The pretreatment derived neutrophils/ (leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) made up the LIPI and divided it into two groups (good, 0 score; poor, 1 to 2 scores). Overall survival (OS), progressionfree survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) were calculated from the date of diagnosis. Kaplan-Meier method and Cox hazards regression analysis were used to explore associations between the LIPI and LA-NSCLC prognosis. Propensity score matching (PSM) was conducted to balance the confounding variables. Results: A total of 1079 patients were eligible for analysis. Patients with a poor pretreatment LIPI had significantly inferior OS, PFS, LRRFS, and DMFS than those with a good LIPI (median OS, 19.0 vs 25.0 months, Log-rank P < 0.001; median PFS, 10.0 vs 13.0 months, Log-rank P ¼ 0.001; median LRRFS, 13.0 vs 18.0 months, Log-rank P < 0.001; median DMFS, 15.0 vs 17.0 months, Logrank P ¼ 0.002). According to multivariate analysis, it was also found that the LIPI was an independent prognostic marker for OS (P ¼ 0.026,